Amylyx launches $164M common stock offering at $10.00 per share to fund avexitide launch

Amylyx Pharmaceuticals, Inc.

Offering of 17.5M shares (2.625M option) at $10.00/share; net proceeds ~$164M, up to ~$188.7M.
Proceeds to advance avexitide commercial readiness, R&D, working capital, and general corporate purposes.
Underwriting led by Leerink Partners and Guggenheim Securities; expected closing September 11, 2025.
Underwriters granted 30-day option to purchase up to 2.625M additional shares at offering price less discounts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.